Jaguar Animal Health (JAGX) AI Stock Analysis

• Market Cap: $7.35M
• Dividend Yield: N/A
• Average Volume (3M): 163.34K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.59
• Revenue Growth: 19.75%
• EPS Growth: 95.65%
• Country: US
• Employees: 49
• Sector: Healthcare
• Sector Strength: 69
• Industry: Biotechnology
• EPS (TTM): -233.19
• Shares Outstanding: 674,005
• 10 Day Avg. Volume: 358,326
• 30 Day Avg. Volume: 163,341
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): 0.26
• Price to Cash Flow (P/CF): -0.10
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: 5.92
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: 5.64
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0

Jaguar Animal Health's overall stock score is low primarily due to substantial financial challenges, including high leverage and negative profitability. Technical analysis suggests bearish trends, and valuation metrics are unappealing. While recent earnings calls and corporate events provide some optimism with revenue growth and potential regulatory advancements, ongoing net losses and clinical trial challenges continue to weigh heavily on the stock's potential.

Jaguar Animal Health Business Overview & Revenue Model

Company Description

Jaguar Health, Inc., a commercial stage pharmaceuticals company, focuses on developing prescription medicines for people and animals with gastrointestinal distress, specifically chronic, and debilitating diarrhea. The company operates through two segments, Human Health and Animal Health. It markets Mytesi for the symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy. The company also develops Crofelemer for multiple possible follow-on indications, including cancer therapy-related diarrhea; orphan-drug indications for symptomatic relief of diarrhea in infants and children with congenital diarrheal disorders and for adult and pediatric patients for short bowel syndrome with intestinal failure with; supportive care for diarrhea relief in inflammatory bowel diseases; diarrhea-predominant irritable bowel syndrome; and for idiopathic/functional diarrhea. In addition, it develops lechlemer, a second-generation anti-secretory agent for cholera; and Canalevia, an oral plant-based drug candidate to treat chemotherapy-induced diarrhea in dogs and exercise-induced diarrhea in dogs. Jaguar Health, Inc. was founded in 2013 and is headquartered in San Francisco, California.

How the Company Makes Money

Jaguar Animal Health generates revenue through the sale of its proprietary pharmaceutical products and royalties from licensing agreements. The company's primary revenue stream comes from the commercialization of Canalevia-CA1, which is sold to veterinary clinics and specialists to treat gastrointestinal conditions in dogs. In addition to direct sales, Jaguar benefits from strategic partnerships and collaborations that expand its research and distribution capabilities, including licensing agreements with pharmaceutical companies that enable it to earn royalties on products developed using its technology. These partnerships also contribute to the company's earnings by providing additional avenues for product development and market penetration.

Jaguar Animal Health Financial Statement Overview

Summary

Jaguar Animal Health is experiencing revenue growth but faces significant profitability and liquidity challenges. The company struggles with substantial losses, a high debt-to-equity ratio, and negative cash flow.

Income Statement

Jaguar Animal Health shows persistent revenue growth, with a TTM revenue of $10.48M, up from $9.76M in 2023. However, the company is struggling with profitability, evidenced by a negative net profit margin and significant EBIT and EBITDA losses. The gross profit margin remains healthy at approximately 68.6%, but the net loss indicates ongoing financial challenges.

Balance Sheet

The balance sheet reveals a high debt-to-equity ratio and limited equity base, with stockholders' equity at $13.61M against $34.27M in total debt. The equity ratio stands at 23.3%, indicating financial leverage concerns. Despite these challenges, there is a noteworthy improvement in stockholders' equity from negative values in previous years.

Cash Flow

The cash flow statement highlights negative operating cash flow and free cash flow, reflecting liquidity issues. The free cash flow growth rate is improving, but the company is still heavily reliant on financing activities. The operating cash flow to net income ratio is negative, emphasizing ongoing cash management challenges.

Breakdown
Dec 2023	Dec 2022	Dec 2021	Dec 2020	Dec 2019
Income Statement		Total Revenue
9.76M	11.96M	4.33M	9.38M	5.78M
	Gross Profit
7.72M	9.94M	2.00M	6.11M	1.96M
	EBIT
-34.29M	-34.41M	-39.07M	-21.30M	-24.95M
	EBITDA
-33.13M	-33.38M	-42.35M	-28.74M	-30.87M
	Net Income Common Stockholders
-41.30M	-47.45M	-60.25M	-36.79M	-38.54M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
6.47M	5.47M	17.05M	8.09M	3.50M
	Total Assets
50.76M	47.45M	53.27M	42.84M	36.41M
	Total Debt
37.09M	34.84M	29.36M	16.21M	7.57M
	Net Debt
30.63M	29.37M	12.31M	8.12M	4.07M
	Total Liabilities
45.87M	48.81M	41.41M	25.64M	25.74M
	Stockholders Equity
4.96M	-657.00K	11.61M	17.20M	10.67M
Cash Flow		Free Cash Flow
-33.24M	-34.78M	-34.98M	-15.29M	-20.46M
	Operating Cash Flow
-33.24M	-33.10M	-34.97M	-15.28M	-20.46M
	Investing Cash Flow
0.00	-1.68M	-6.00K	-7.00K	0.00
	Financing Cash Flow
34.23M	23.18M	43.94M	19.49M	21.77M

Jaguar Animal Health Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 10.91
• 50DMA: Positive
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Negative
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JAGX, the sentiment is Positive. The current price of 10.91 is above the 20-day moving average (MA) of 5.61, above the 50-day MA of 10.48, and below the 200-day MA of 26.24, indicating a neutral trend. The MACD of -0.44 indicates Negative momentum. The RSI at 70.55 is Negative, neither overbought nor oversold. The STOCH value of 70.58 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for JAGX.

Jaguar Animal Health Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51 Neutral	$5.31B	3.39	-40.42%	2.90%	18.11%	2.25%
HSCS	41 Neutral	$3.46M	―	-163.47%	―	-100.00%	78.91%
JAGX	39 Underperform	$7.35M	―	-522.60%	―	19.75%	95.65%
TTNP	35 Underperform	$3.38M	―	-103.63%	―	-100.00%	28.48%

Jaguar Animal Health Corporate Events

Jaguar Health Presents at Elite Ped-GI Congress 2025

Jaguar Health announced its participation in the 11th Annual Elite Ped-GI Congress 2025 in Abu Dhabi, where they will present proof-of-concept data for their products, including crofelemer. The company is actively pursuing business development opportunities and regulatory designations in the U.S. and Europe, aiming to expand the market reach of crofelemer for various indications, which could significantly impact their market positioning and stakeholder interests.

Spark’s Take on JAGX Stock

According to Spark, TipRanks’ AI Analyst, JAGX is a Neutral.

Jaguar Animal Health is currently facing substantial financial difficulties with high leverage and negative profitability, as reflected in the financial performance and valuation scores. Technical analysis suggests bearish trends, while recent earnings calls and corporate events provide some optimism with revenue growth and potential regulatory advancements. However, the company’s ongoing net losses and challenges in clinical trials continue to weigh on its overall stock score.

To see Spark’s full report on JAGX stock, click here.

Jaguar Animal Health Secures $3.448M in Private Placement

On March 31, 2025, Jaguar Health closed a private placement, raising approximately $3.448 million through convertible promissory notes and warrants. The funds will be used for working capital and general corporate purposes, with expectations of key catalysts in the second quarter of 2025 related to crofelemer development for rare diseases and cancer therapy-related diarrhea, potentially enhancing the company’s value.

Jaguar Animal Health Announces Reverse Stock Split

Jaguar Health, Inc. announced a reverse stock split of its common stock at a 1-for-25 ratio, effective March 24, 2025, to comply with Nasdaq listing standards and attract institutional investors. The reverse stock split will reduce the number of shares and increase the share price, with no fractional shares issued; stockholders will receive cash for any fractional shares. The company’s stock will continue trading on Nasdaq under the symbol ‘JAGX’ with a new CUSIP number.

Jaguar Animal Health Advances Crofelemer for Rare Diseases

On March 13, 2025, Jaguar Health held a special meeting where stockholders approved two proposals, including a reverse stock split of the company’s common stock. The company is advancing its plant-based drug, crofelemer, for rare diseases and cancer therapy-related diarrhea, with expected trial results and regulatory discussions in 2025. These developments could enhance Jaguar’s market positioning and offer new treatment pathways, potentially benefiting stakeholders.